An Effective Intervention: Limiting Opioid Prescribing as a Means of Reducing Opioid Analgesic Misuse,and Overdose Deaths

Abstract

Overdose deaths involving prescription opioids killed more than 17,000 Americans in 2017, marking a five-fold increase since 1999. High prescribing rates of opioid analgesics have been a substantial contributor to prescription opioid misuse, dependence, overdose and heroin use. There was recognition approximately ten years ago that opioid prescribing patterns were contributing to this startling increase in negative opioid-related outcomes, and federal actions, including Medicare reimbursement reform and regulatory actions, were initiated to restrict opioid prescribing. The current manuscript is a description of those actions, the effect of those actions on opioid prescribing and related patient outcomes. We also describe our proposal of methods of expanding these efforts as an important piece to further reduce opioid-related misuse, dependence, and overdose death.

Get full access to this article

View all access options for this article.

References

G. P.

Guy, Jr.,

Zhang ,

M. K.

Bohm , et al., “Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015, MMWR Morbitity Mortality Weekly Report 66, no. 26 (2017): 697-704.

R. D.

deShazo ,

Johnson ,

Eriator , and

Rodenmeyer , “Backstories on the US Opioid Epidemic: Good Intentions Gone Bad, An Industry Gone Rogue, and Watch Dogs Gone to Sleep,” American Journal of Medicine 131, no. 6 (2018): 595-601.

Centers for Disease Control and Prevention (CDC), Multiple Cause of Death 1999-2017, available at <http://wonder.cdc.gov/mcd-icd10.html> (last visited April 3, 2020);

A.S.

Bohnert ,

Valenstein ,

M. J.

Bair , et al., “Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths,” Journal of the American Medical Association 305, no. 13 (2011): 1315-1321.

See CDC, supra note 3.

G. P.

Guy, Jr.,

Zhang ,

L. Z.

Schieber ,

Young , and

Dowell , “County-Level Opioid Prescribing in the United States, 2015 and 2017,” Journal of the American Medical Association: Internal Medicine 179, no. 4 (2019): 574-576.

“Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health,” (2018); HHS Publication No. SMA 18-5068 NSDUG Series H-53, available at <https://www.samhsa.gov/data> (last visited April 6, 2020).

See SAMHSA, supra note 7.

Centers for Disease Control and Prevention (CDC), U.S. Opioid Prescribing Rate Maps (2019), available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (2019) (last visited April 3, 2020).

10.

FDA, FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends (Washington, DC: Food and Drug Administration, 2018), available at <https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM598899.pdf> (last visited April 3, 2020);

M. D.

DiBonaventura ,

Sadosky ,

Concialdi , et al., “The Prevalence of Probable Neuropathic Pain in the US: Results from a Multimodal General-Population Health Survey,” Journal of Pain Research 10, no. 2017 (2017): 2525-2538.

11.

Wunsch ,

D. N.

Wijeysundera ,

M. A.

Passarella , and

M. D.

Neuman , “Opioids Prescribed After Low-Risk Surgical Procedures in the United States, 2004-2012,” Journal of the American Medical Association 315, no. 15 (2016): 1654-1657.

12.

M. C.

Bicket ,

J.J.

Long ,

P. J.

Pronovost ,

G. C.

Alexander , and

C. L.

Wu , “Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review,” Journal of the American Medical Association: Surgery 152, no. 11 (2017): 1066-1071.

13.

K. M.

Theisen ,

J. M.

Myrga , and

Hale , et al. “Excessive Opioid Prescribing After Major Urologic Procedures,” Urology 123 (2019): 101-107.

14.

See Bicket, supra note 12.

15.

See SAMHSA, supra note 7.

16.

C. M.

Brummett ,

J. F.

Waljee , and

Goesling , et al., “New Persistent Opioid Use after Minor and Major Surgical Procedures in US Adults,” Journal of the American Medical Association: Surgery 152, no. 3 (2017): e170504.

17.

See Brummett, supra note 16;

W. M.

Hooten ,

J. L.

St. Sauver ,

M. E.

McGree ,

D. J.

Jacobson , and

D. O.

Warner , “Incidence and Risk Factors for Progression From Short-term to Episodic or Long-term Opioid Prescribing: A Population-Based Study,” Mayo Clinic Proceedings 90, no. 7 (2015): 850-856.

18.

See Brummet, supra note 16;

Wunsch ,

D. N.

Wijeysundera ,

M. A.

Passarella , and

M. D.

Neuman , “Opioids Prescribed after Low-Risk Surgical Procedures in the United States, 2004-2012,” The Journal of the American Medical Association 315, no. 15 (2016): 1654-1657.

19.

Dowell ,

T. M.

Haegerich , and

Chou , “CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016,” Journal of the American Medical Association. 315, no. 15 (2016): 1624-1645.

20.

Shah ,

C. J.

Hayes , and

B. C.

Martin , “Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006-2015,” MMWR Morbitity and Mortality Weekly Report 66, no. 10 (2017): 265-269.

21.

See Shah, supra note 20.

22.

See Shah, supra note 20.

23.

See Dowell, supra note 19.

24.

A. M.

Peckham ,

K. A.

Fiarman ,

Awanis , and

N. K.

Early , “High-Risk Opioid Prescribing Trends in the Outpatient Setting Prior to Issuance of Federal Guidance,” Preventive Medicine Reports 15 (2009): 100892.

25.

Centers for Disease Control and Preventions, “Vital Signs: Overdoses of Prescription Opioid Pain Relievers — United States, 1999-2008,” MMWR Morbitity Mortality Weekly Report 60, no. 43 (2011): 1487-1492.

26.

W. M.

Compton ,

C. M.

Jones , and

G. T.

Baldwin , “Relationship Between Nonmedical Prescription-Opioid Use and Heroin Use,” New England Journal of Medicine 374, no. 2 (2016): 154-163.

27.

P. K.

Muhuri ,

J. C.

Gfroerer , and

M. C.

Davies , “Assciations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States,” Centers for Behavioral Health Statistics and Quality Data Review (2013) 1-17, available at <http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf> (Last visited April 6, 2020).

28.

Substance Abuse and Mental Health Services Administration (SAMHSA), “Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health,” (2018), HHS Publication No. SMA 18-5068 NSDUG Series H-53, available at <https://www.samhsa.gov/data> (Last visted April 5, 2020).

29.

See Compton, supra note 26.

30.

Federal Drug Administration (FDA), “FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends,” (Washington, DC: Food and Drug Administration, 2018), available at <https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM598899.pdf> (last visited April 5, 2020).

31.

See CDC, supra note 3.

32.

M. C.

Garcia ,

A. B.

Dodek , and

Kowalski , et al., “Declines in Opioid Prescribing after a Private Insurer Policy Change — Massachusetts, 2011-2015,” MMWR Morbitity and Mortality Weekly Report 65, no. 41 (2016): 1125-1131.

33.

Food and Drug Administration, “FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends,” (Washington, DC: Food and Drug Administration; 2018).

34.

C. M.

Jones ,

P. G.

Lurie , and

D. C.

Throckmorton , “Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing,” Journal of the American Medical Association: Internal Medicine 176, no. 3 (2016): 399-402.

35.

See Jones, supra note 33.

36.

Drug Enforcement Agency, “DEA Reduces Amount of Opioid Controlled Substances to be Manufactured in 2017,” (2016), available at <https://www.dea.gov/press-releases/2016/10/04/dea-reduces-amount-opioid-controlled-substances-be-manufactured-2017> (last visited April 5, 2020).

37.

FDA, Oxymorphone (marketed as Opana ER) Information, (2017), available at <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm562339.htm> (last visited April 5, 2020).

38.

Broz ,

Zibbell , and

Foote , et al., “Multiple Injections Per Injection Episode: High-Risk Injection Practice Among People who Injected Pills During the 2015 HIV Outbreak in Indiana,” International Journal on Drug Policy 52 (2018): 97-101.

39.

Rutkow ,

J. S.

Vernick , and

G. C.

Alexander , “More States Should Regulate Pain Management Clinics to Promote Public Health,” American Journal of Public Health 107, no. 2 (2017): 240-243.

40.

Johnson ,

Paulozzi ,

Porucznik ,

Mack , and

Herter , “Decline in Drug Overdose Deaths after State Policy Changes — Florida, 2010-2012,” MMWR Morbitity and Mortality Weekly Report 63, no. 26 (2014): 569-574.

41.

E. E.

McGinty ,

E. A.

Stuart ,

Caleb Alexander ,

C. L.

Barry ,

M. C.

Bicket , and

Rutkow , “Protocol: Mixed-Methods Study to Evaluate Implementation, Enforcement, and Outcomes of U.S. State Laws Intended to Curb High-Risk Opioid Prescribing,” Implementation Science 13, no. 1 (2018): 37.

42.

Prescribing Policies: States Confront Opioid Overdose Epidemic, (2017), available at <http://www.ncsl.org/Portals/1/Documents/Health/prescribingOpioids_final01-web.pdf> (last visited April 5, 2020).

43.

See Prescribing Policies, id.

44.

R. M.

Henke ,

A. B.

Tehrani ,

M. M.

Ali ,

Mutter ,

Mazer-Amirshahi ,

P. L.

O'Brien , and

T. L.

Mark , “Opioid Prescribing to Adolescents in the United States from 2005-2016,” Psychiatric Services 69, no. 9 (2018): 1040-1043.

45.

Huang ,

K. M.

Keyes , and

Li , “Increasing Prescription Opioid and Heroin Overdose Mortality in the United States, 1999-2014: An Age-Period-Cohort Analysis,” American Journal of Public Health 108, no. 1 (2018): 131-136.

46.

S. G.

Kertesz ,

S. L.

Satel ,

DeMicco ,

R. C.

Dart , and

D. P.

Alford , “Opioid Discontinuation as an Institutional Mandate: Questions and Answers on Why we Wrote to the Centers for Disease Control and Prevention,” Substance Abuse 40, no. 4 (2019), DOI: 10.1080/08897077.2019.1635973

47.

T. R.

Kosten ,

L. E.

Baxter , “Effective Management of Opioid Withdrawal Symptoms: A Gateway to Opioid Dependence Treatment,” The American Journal on Addiction 28, no. 2 (2019): 55-62.

48.

See Kosten, supra note 47.

49.

50.

See FDA, supra note 49.

51.

See SAMHSA, supra note 28.

52.

M. N.

Wilson ,

J. A.

Hayden ,

Rhodes ,

Robinson , and

Asbridge , “Effectiveness of Prescription Monitoring Programs in Reducing Opioid Prescribing, Dispensing and use Outcomes: A Systematic Review,” Journal of Pain 20, no. 12 (2019), doi: 10.1016/j.jpain.2019.04.007.

53.

Khobrani ,

Perona , and

A. S.

Patanwala , “Effect of a Legislative Mandate on Opioid Prescribing for Back Pain in the Emergency Department,” American Journal of Emergency Medicine 37, no. 11 (2019). doi.org/10.1016/j.ajem.2019.02.031.

54.

B. C.

Sun ,

C. J.

Charlesworth , and

Lupulescu-Mann , et al., “Effect of Automated Prescription Drug Monitoring Program Queries on Emergency Department Opioid Prescribing,” Annals of Emergency Medicine 71, no. 3 (2017): 337-347.

55.

S. G.

Weiner ,

C. N.

Price ,

A. J.

Atalay ,

E. M.

Harry ,

E. A.

Pabo , et al., “A Health System-Wide Initiative to Decrease Opioid-Related Morbidity and Mortality,” Joint Commission Journal on Quality and Patient Safety 45, no. 1 (2019): 3-13.

56.

See CDC, supra note 3.

57.

McDonald ,

N. D.

Campbell , and

Strang , “Twenty Years of Take-Home Naloxone for the Prevention of Overdose Deaths from Heroin and other Opioid: Conception and Maturation,” Drug and Alcohol Dependence 178, (2017): 176-187.

58.

Levy ,

Spelke , and

L. J.

Paulozzi LJ, et al., “Recognition and Response to Opioid Overdose Deaths: New Mexico 2012,” Drug and Alcohol Dependence 167 (2016): 29-35.

59.

Comerci ,

Katzman , and

Duhigg , “Controlling the Swing of the Opioid Pendulum,” New England Journal of Medicine 378, no. 8 (2018): 691-693, doi: 10.1056/NEJMp1713159.

60.

P. K.

Muhuri ,

J. C.

Gfroerer , and

Davies , “Assciations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States,” CBHSQ Data Review (2013), available at <http://www.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf> (last visited April 8, 2020).

61.

Miech ,

Johnston ,

P. M.

O'Malley ,

K. M.

Keyes , and

Heard , “Prescription Opioids in Adolescence and Future Opioid Misuse” Pediatrics 136, no. 5 (2015): e1169-1177. doi: 10.1542/peds.2015-1364.

62.

Guarino ,

Mateu-Gelabert ,

Teubl , and

Goodbody , “Young Adults' Opioid Use Trajectories: From Nonmedical Prescription Opioid Use to Heroin, Drug Injection, Drug Treatment and Overdose,” Addictive Behaviors 86 (2018): 118-123, doi: 10.1016/j.addbeh.2018.04.017.

63.

Noble ,

J. R.

Treadwell ,

S. J.

Tregear ,

V. H.

Coates ,

P. J.

Wiffen ,

Akafomo , and

K. M.

Schoelles , “Long-Term Opioid Management for Chronic Non-cancer Pain,” Cochrane Database Systematic Reviews 1 (2010): 1–64.

64.

A. N.

Malani ,

P. G.

Richards ,

Kapila ,

M. H.

Otto ,

Czerwinski , and

Singal , “Clinical and Economic Outcomes from a Community Hospital's Antimicrobial Stewardship Program,” American Journal of Infection Control 41, no. 2 (2013): 190-197.

65.

S. G.

Weiner ,

C. N.

Price , and

A. J.

Atalay , et al., “A Health System-Wide Initiative to Decrease Opioid-Related Morbidity and Mortality,” Joint Commission Journal on Quality and Patient Safety 45, no. 1 (2019): 3-13.

66.

See SAMHSA, supra note 28.

67.

See CDC, supra note 3.

68.

See McGinty, supra note 40;

A. M.

Parker ,

Strunk , and

D. A.

Fiellin , “State Responses to the Opioid Crisis,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 367-381.

69.

Supra note 23.

70.

Supra note 17.

71.

Supra note 35.

72.

Supra note 19.

73.

Supra note 24.

74.

Supra note 25.

75.

Supra note 17.

76.

Supra note 18.

77.

Supra note 17.

78.

Supra note 24.

79.

Supra note 25.

80.

Supra note 18.

81.

Supra note 23.

82.

Supra note 22.

83.

Supra note 35.

84.

Supra note 20.

85.

Supra note 17.